Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, single ascending dose trial and a multiple ascending dose, proof-of-concept trial of TERN-601.

Next Previous
Trial Profile

A Phase 1, single ascending dose trial and a multiple ascending dose, proof-of-concept trial of TERN-601.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TERN-601 (Primary)
  • Indications Obesity
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Terns Pharmaceuticals

Most Recent Events

  • 25 Feb 2025 According to a Terns Pharmaceuticals media release, company announced that management will participate in the TD Cowen 45th Annual Healthcare Conference taking place from March 3-5, 2025 in Boston and provided program updates across the Companys development programs
  • 09 Sep 2024 According to a Terns Pharmaceuticals media release, company announced positive top-line data from its Phase 1 randomized, double-blind, placebo-controlled single and multiple-ascending dose (SAD and MAD) trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TERN-601 dosed once-daily (QD) in healthy adults with obesity or overweight.
  • 05 Aug 2024 According to a Terns Pharmaceuticals media release, company is on track to report safety and 28-day weight loss data in September 2024 from the Phase 1 first-in-human clinical trial of TERN-601.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top